as 05-20-2024 1:32pm EST
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Founded: | 2003 | Country: | United States |
Employees: | N/A | City: | ROCKVILLE |
Market Cap: | 16.9M | IPO Year: | 2014 |
Target Price: | $12.00 | AVG Volume (30 days): | 1.5M |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.58 | EPS Growth: | N/A |
52 Week Low/High: | $0.26 - $3.53 | Next Earning Date: | 05-09-2024 |
Revenue: | $10,000 | Revenue Growth: | -86.67% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GLYC Breaking Stock News: Dive into GLYC Ticker-Specific Updates for Smart Investing
Associated Press Finance
11 days ago
Clinical Trials Arena
12 days ago
Clinical Trials Arena
13 days ago
MT Newswires
14 days ago
MT Newswires
14 days ago
Business Wire
14 days ago
Simply Wall St.
22 days ago
Business Wire
25 days ago